About CancerIQ
CancerIQ is a Healthcare company based in Chicago (United States) founded in 2013. CancerIQ is focused on precision cancer prevention and care. It operates on a SaaS (Software-as-a-Service) and HealthTech model. CancerIQ has raised $23.87 million across 6 funding rounds from investors including Amgen, McKesson and Decathlon Capital Partners. The company has 78 employees. Its chief executive, as recorded, is Feyi Olopade. Its website canceriq.com draws about 21 thousand monthly visits. CancerIQ offers products and services including CancerIQ Platform and Telehealth Genetic Counseling. Its focus areas include Health Technology and Oncology Software. Its legal entity is CancerIQ, Inc. Its competitors include Tempus, Personalis and Perthera; 3 of its 3 listed competitors have raised funding.
Company details
CancerIQ is engaged in providing software solutions for health systems to enhance access to genomics and oncology innovations. The company operates in the healthcare sector, specifically targeting oncology, genetics, and breast health programs. Its integrated intelligence solution is designed to improve clinical and financial outcomes by addressing workforce challenges and ensuring adherence to medical management recommendations. Tools for risk assessment, patient navigation, and care plan management are offered, alongside connections to telehealth genetic counseling networks. The platform supports providers with clinical decision tools and evidence-based guidelines while enabling seamless integration with electronic health records (EHRs).
- Headquarters Chicago, United States
- Employees 78
- SectorsHealthcare
- Phone•••• ••••
- Website canceriq.com
- Social LinkedIn X Facebook
- Legal Name Canceriq, Inc.
- Total Equity Funding$23.87M (USD)
in 6 rounds
- InvestorsAmgen
& 8 more
- Employee Count78
Products & Services of CancerIQ
CancerIQ offers a comprehensive portfolio of products and services, including CancerIQ Platform and Telehealth Genetic Counseling.
Software for cancer risk assessment and management.
Connects patients to genetic counseling via telehealth.
Funding Insights of CancerIQ
CancerIQ has successfully raised a total of $23.87M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.87M
- Total Rounds 6
- First Round $100,000
(Jun 2013)
- Investors Count 9
All 6 funding rounds of CancerIQ with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | Series B | – | Decathlon Capital Partners | – | |
| Nov 2023 | $3.35M | Series B | – | – | – |
| Mar 2022 | $14M | Series B | – | Merck Global Health Innovation Fund, Amgen | |
| Aug 2020 | $4.8M | Series A | – | HealthX Ventures | |
| Apr 2020 | $1.62M | Seed | – | – | – |
| Jun 2013 | $100,000 | Seed | – | – |
9 investors in total: 9 institutional.
Investors in CancerIQ
CancerIQ has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, McKesson and Decathlon Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private debt funds focused on direct lending, and revenue-based financing | 2010 | decathloncapital.com | Palo Alto, United States | |
Corporate-backed venture capital is focused on the life science sector. | merckghifund.com | Kenilworth, United States | ||
| osfventures.org | ||||
Investments are directed toward accessible digital healthcare solutions. | healthxventures.com | Madison, United States | ||
Venture capital is provided to economic, sustainability, and health sectors. | theimpactengine.com | Chicago, United States | ||
Tech focused seed & early stage VC firm investing primarily in the US | lightbank.com | Chicago, United States | ||
Digital Health focused VC & Accelerator firm investing in the US | rockhealth.com | San Francisco, United States | ||
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Products and services are provided in the healthcare industry. | 1833 | mckesson.com | Irving, United States |
Investor details for CancerIQ
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CancerIQ
18 people are tracked at CancerIQ (10 in leadership, 8 in team); the tracked headcount is 78.
| Name | Role | Group |
|---|---|---|
Feyi Olopade | CEO | Leadership |
Ben Bowman | CFO | Leadership |
Olufunmilayo Olopade | Co-Founder, Chief Scientific Officer | Leadership |
Melissa Netto | Director Of Engineering And Customer Success | Leadership |
Feyi Olopade Ayodele | Co-founder & CEO | Leadership |
Laku Adedoyin | Chief Technology Officer | Leadership |
Anitha Sivaraman | Director Of QA And Support | Leadership |
Kat Kostolansky | Director Of Business Development | Leadership |
Malvina Kefalas | Director of Marketing | Leadership |
Chartfield Bliss | Vice President Operations | Leadership |
William Johnson | Senior Software Engineer | Team |
Alejandro Davila | Principal Software Engineer | Team |
Benjamin Johnson | Senior Software Engineer | Team |
Chase Brewer | Software Engineer | Team |
Joy Benjauthrit | Business Analyst - Integration | Team |
Mark Lu | Senior Software Engineer | Team |
Karen Awan | Executive Operations | Team |
Haibo Lu | Advisor | Team |
Complete people profiles for CancerIQ
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CancerIQ
3 dated milestones of CancerIQ across 11 years, from founding to its latest funding, stage changes and deals.
- Founded CancerIQ is founded.
- Funding First funding round of $100K.
- Funding Latest funding round, Series B,.
Competitors of CancerIQ
CancerIQ has 3 listed competitors in our database, 3 of them funded. They include Tempus, Personalis and Perthera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tempus.com | 2015 | Chicago, United States | $1.05B | 772 | AI-based precision medicine solutions for oncology are provided. | |
| personalis.com | 2011 | Menlo Park, United States | $87.3M | 310 | Genomic sequencing and diagnosis software is provided for healthcare. | |
| perthera.com | 2012 | Mclean, United States | $17.02M | 13 | Molecular cancer profiling is conducted via genomics and proteomics. |
Detailed competitors of CancerIQ
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CancerIQ
The website of CancerIQ (canceriq.com) receives about 21.3K visits a month.
- Monthly visits21.3K
▲ 18.6% vs previous month
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as CancerIQ (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Canceriq
Complete news archive for CancerIQ
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CancerIQ
CancerIQ was founded in 2013.
CancerIQ is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Feyi Olopade is the CEO of CancerIQ, as recorded in our data.
CancerIQ is a funded company, having raised a total of $23.87M across 6 funding rounds to date. The company's 1st funding round was a Seed of $100K, raised on Jun 2013.
CancerIQ has 78 employees.
CancerIQ is engaged in providing software solutions for health systems to enhance access to genomics and oncology innovations. The company operates in the healthcare sector, specifically targeting oncology, genetics, and breast health programs. Its integrated intelligence solution is designed to improve clinical and financial outcomes by addressing workforce challenges and ensuring adherence to medical management recommendations. Tools for risk assessment, patient navigation, and care plan management are offered, alongside connections to telehealth genetic counseling networks. The platform supports providers with clinical decision tools and evidence-based guidelines while enabling seamless integration with electronic health records (EHRs).
CancerIQ's top competitors include Tempus, Personalis and Perthera.
CancerIQ offers CancerIQ Platform and Telehealth Genetic Counseling.
CancerIQ has 9 investors. Key investors include Amgen, McKesson, Decathlon Capital Partners, Merck Global Health Innovation Fund, and OSF Ventures.
CancerIQ operates through Canceriq, Inc..